Vedolizumab As First-Line Biological Therapy in Elderly Patients and Those with Contraindications for Anti-Tnf Therapy: a Real-World, Nationwide Cohort of Patients with Inflammatory Bowel Diseases.

Mohamed Attauabi, Camilla Hoglund,Janne Fassov, Kenneth Bo Pedersen, Heidi Bansholm Hansen,Signe Wildt,Michael Dam Jensen,Anders Neumann, Cecilie Lind,Henrik Albaek Jacobsen, Ana-Maria Popa,Jens Kjeldsen,Natalia Pedersen,Akbar Molazahi, Kent Haderslev,Claus Aalykke,Torben Knudsen, Wojciech Cebula,Pia Munkholm,Flemming Bendtsen,Jakob Benedict Seidelin,Johan Burisch

Scandinavian Journal of Gastroenterology（2021）

引用 11|浏览16

暂无评分

关键词

Inflammatory bowel disease,ulcerative colitis,Crohn's disease,vedolizumab,real-world,efficacy,safety,first-line biologics,bio-naive,nationwide,population-based

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要